Alvogyl

Quick links

Choose a section

Quick links to important sections

Advertisements

Alvogyl

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Alvogyl

Quick Facts

Property Description
Active Ingredients Lidocaine Hydrochloride, Eugenol, Iodoform
Form Paste (Non-resorbable dressing)
Pharmacological Class Local Anesthetic, Antiseptic, Analgesic
Common Use Post-extraction socket management
Origin Pharmaceutical Combination (Natural and Synthetic)

Alvogyl: Definition and Pharmacological Classification

Alvogyl (also known as Alveogyl) is a specialized pharmaceutical combination used as a dental preparation for managing post-extraction surgical sites, a typical use scenario following routine tooth extraction. This compound is classified by dental professionals as an agent that simultaneously provides Local Anesthetic, Antiseptic, and Analgesic effects. The preparation is utilized as a single-use dressing designed for localized topical application. Lidocaine Hydrochloride, one of its primary components, is consistently recognized as an amide-type local anesthetic. This classification confirms the preparation's primary role in achieving immediate localized pain desensitization.

Composition and Physical Form of the Dental Paste

The identity of Alvogyl is defined by its three distinct active ingredients: Lidocaine Hydrochloride, Eugenol, and Iodoform. These chemical substances furnish the preparation's triple therapeutic capability. The preparation is supplied as a viscous paste, which is the defined dosage form for this specialized dental preparation. The essential role of Eugenol as an analgesic and anti-inflammatory agent in dental applications has been clinically recognized. This inclusion of Eugenol is intended to ensure a complementary sedative effect and sustained tissue support. Its composition is derived from both synthetic components and a component of natural derivation (Eugenol). This specific paste form is a key differentiating feature, explicitly categorized as non-resorbable so that it remains in the application site until it is physically removed by the dental professional.

General Purpose: How the Triple-Action Formula Helps

The general purpose of Alvogyl is to achieve both pain desensitization and effective microbial inhibition in the local area concurrently. The Lidocaine Hydrochloride component delivers focused analgesic relief by blocking nerve signals, while the Eugenol provides a complementary, localized sedative effect on nerve endings. The inclusion of Iodoform ensures an essential antiseptic mechanism. This integrated triple action supports localized comfort and management, leveraging the sustained presence provided by the paste dressing.

Advertisements

What side effects are possible with Alvogyl?

Possible Side Effects and Safety Information

The safety characteristics of the Alvogyl dental paste are predominantly defined by its localized application and its core property as a non-resorbable dressing. Official documentation on adverse reactions primarily focuses on localized events at the application site, rather than a systemic side-effect profile.

Adverse Reactions and Tissue Response

The most significant safety pattern documented is the potential for a Foreign-Body Reaction (FBR) and subsequent Chronic Inflammatory Response within the alveolar tissue. Since the material contains non-resorbable components, it is not spontaneously eliminated from the socket, and its persistence can induce this tissue reaction. This localized response is associated with complications in wound healing, including reported cases of Delayed Healing and Local Infection at the site of extraction.

Serious Adverse Reactions and Restrictions

In rare, documented instances, the localized tissue response has been associated with serious outcomes. These include reports of Severe Facial Cellulitis and the development of persistent lesions that may cause Diagnostic Pitfalls for pathologists, as their appearance can be confused with other serious conditions. The preparation is contraindicated in individuals with known hypersensitivity or allergy to its active ingredients, which include Lidocaine Hydrochloride, Eugenol, and Iodoform. Furthermore, safety data is limited, or exclusion criteria are applied to special populations, such as pediatric and pregnant patients, in relevant clinical investigations.

Advertisements

Overdose and Emergency Response

The official regulatory documents for the active components of Alvogyl define the profile of systemic overdose, even though the product is for localized use. The primary concern is neurotoxicity, which may initially manifest as lightheadedness, dizziness, confusion, tremors, or tinnitus. This may escalate to severe outcomes including convulsions, unconsciousness, and respiratory arrest.

Severe Outcomes and Immediate Action

Life-threatening complications documented in regulatory sources also include severe cardiovascular instability, specifically bradycardia, hypotension, and the risk of cardiac arrest. Other serious metabolic and organ risks are Methemoglobinemia and acute liver damage.

Immediate medical attention is required for any signs of systemic toxicity or suspected accidental ingestion. Regulatory guidance mandates that patients must seek immediate emergency help or contact a Poison Control Center if these systemic signs appear. Supportive management is symptomatic and procedural, including the use of activated charcoal and providing breathing support. Infants, children, and patients with severe hepatic disease are specifically noted to have an increased susceptibility to severe or toxic concentrations. Close monitoring of vital signs is officially recommended.

Advertisements

Therapeutic Uses of Alvogyl

What Alvogyl Treats: Main Uses and Benefits

Alvogyl is commonly used in conditions characterized by periods of heightened symptoms following tooth extraction, particularly in the management of post-extraction complications like Alveolar Osteitis (Dry Socket). The preparation is applied in clinical settings that involve acute or disruptive symptom patterns, and it is relevant when short-term symptomatic assistance is needed in situations requiring additional management of discomfort.

The preparation is relevant for addressing symptoms related to physical discomfort and localized irritation. Specifically, it is relevant for easing severe, throbbing pain that may radiate to the ear, and for supportive management against potential microbial contamination. This supportive application provides support that helps ease the overall symptom burden and may assist patients with managing symptomatic episodes.

It is commonly used across conditions presenting with acute episodes, such as Dry Socket, and is relevant in clinical contexts that involve supportive dressing following complex extractions. It assists with maintaining functional stability and contributes to easing the overall symptom load during periods of heightened symptoms.

“This supportive application is relevant for symptomatic relief and localized protection, supporting the patient during difficult episodes of discomfort.”

Quick Fact: Relevant for Managing Severe Postoperative Pain and Alveolar Tissue Irritation

Advertisements

Eligibility and Restrictions for Use

Population Eligibility for Alvogyl

Official regulatory documents define strict eligibility criteria and absolute contraindications for the use of Alvogyl (Iodo Pengha).

Who Cannot Use Alvogyl (Contraindications)

The medicine is absolutely contraindicated and must not be used in specific populations with known sensitivities:

  • Patients with a history of allergic reactions to procaine-type anaesthetics.
  • Patients with a history of sensitivity to iodine or iodine compounds.

Who Can Use Alvogyl (Approved Indications)

Use is restricted to patients with specific post-extraction complications or risk factors:

  • Individuals requiring treatment of Alveolar Osteitis (Dry Socket).
  • Individuals requiring a post-extraction dressing following a difficult or traumatic extraction.

Special Population Restrictions

Official labeling addresses eligibility for certain demographic groups as follows:

  • Pregnancy and Lactation: Use in these populations is not established, as regulatory documents state that no data is available.
  • Routine Use: The medicine is not recommended for routine use as a general post-extraction dressing; application is conditional on the indicated clinical scenario.
  • Age and Organ Function: There are no specific restrictions stated in the regulatory documentation concerning age-groups (pediatric or geriatric) or patients with hepatic or renal impairment.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documents structure the official interaction profile for Alvogyl around the potential systemic effects of its active component, Lidocaine Hydrochloride, despite its formulation as a non-resorbable dental paste. This profile defines documented interaction patterns based on metabolic and pharmacodynamic mechanisms.


Documented Interaction Patterns

Interaction Type Interacting Agent Categories
Pharmacodynamic Risk Other Local Anesthetics, Class I Antiarrhythmics (e.g., Mexiletine)
Pharmacokinetic Risk CYP1A2/CYP3A4 Inhibitors, Beta-Blockers, Cimetidine
Toxicity Amplification Oxidizing Agents (increase risk of methemoglobinemia)

Official Interaction Statements

Co-administration with other local anesthetics or Class I antiarrhythmic drugs may result in additive systemic toxic effects, according to regulatory labeling. Substances that inhibit CYP1A2 or CYP3A4, such as Cimetidine, are officially noted to increase the plasma concentrations of Lidocaine by impairing its hepatic clearance. Furthermore, the risk of developing methemoglobinemia is increased when co-administered with other agents that possess this specific toxicity risk. Population-specific cautions note that patients with severe hepatic disease are at greater risk of toxic blood concentrations due to impaired metabolism.

Advertisements

Mechanism of Action

Functional Blockade of Peripheral Neural Signaling

This domain focuses on the active binding of the Butamben component to voltage-gated sodium channels (Nav) in sensory nerve membranes. This concentration-dependent blockade prevents the necessary influx of sodium ions, functionally stabilizing the neuron and inhibiting the conduction of afferent electrical signals, which leads to the functional abolition of impulse conduction.


Dual Modulation of Inflammatory and Neural Pathways

The Eugenol component exerts a dual mechanistic effect: it inhibits enzymes in the Arachidonic Acid Cascade (COX-2 and 5-LOX), which restricts the biosynthesis of lipid mediators. This modulation of biochemical pathways reduces peripheral nerve excitability and concurrently promotes a modulatory effect on exposed nerve endings.


Chemical Disruption of Microbial Viability

The Iodoform component ensures an antiseptic mechanism through the slow, localized release of nascent iodine upon contact with tissue. This elemental iodine chemically oxidizes and denatures the essential proteins and enzymes within microbial cell structures, which results in chemical inactivation of microbial cellular components and modulation of local bacterial load.

Advertisements

Dosage and Administration Information

Alvogyl is utilized exclusively for local administration by a dental professional. Its usage principles are strictly defined as a single-application treatment pattern. The preparation is supplied as a paste, a dosage form designed for direct placement into the alveolar socket following a tooth extraction. The local administration route ensures targeted delivery to the required site, bypassing the systemic circulation.

The dosing is standardized for a single event. The required dose is an approximate quantity of 0.20 g of the paste. This amount is specified to be sufficient to adequately cover the bottom of the socket. The required method of application involves using a pair of sterilised tweezers to gently pack the paste into the intended site. This technical constraint emphasizes that the product is designated strictly for use by a professional dental user. Furthermore, the contents of the container should be used within two years of opening to maintain product quality, a key instruction tied to proper use.

The duration of use is governed by a self-eliminating pattern. Unlike traditional dressings that require follow-up removal, Alvogyl is formulated to adhere to the alveolus and gradually dissipate on its own. This means the dressing remains in place for the necessary short-term period as the wound heals naturally, and the single application constitutes the entire treatment course. No explicit dosage adjustments are noted for specific populations such as older adults, as the treatment is strictly localized.

Advertisements

Recent Clinical Evidence

Research Evidence: Overview of Studies for Alvogyl

This section provides a summary of the official research, including key clinical trials and scientific reviews, that describe the evaluation of Alvogyl as a dental dressing. It focuses on the types of evidence that exist, the populations studied, and what primary outcomes were measured.


Evidence for Use in Alveolar Osteitis (Dry Socket)

Short-term Randomized Controlled Trials (RCTs) form the primary structure of research on Alvogyl. These studies typically involved adult patients diagnosed with Alveolar Osteitis (often called Dry Socket), usually following the extraction of a mandibular third molar. The research examined patient-reported outcomes describing perceived discomfort, typically tracked using validated pain scales. Studies monitored how symptoms evolved in the observed populations and research highlights changes measured during the study period for those using the Alvogyl dressing compared to other dressings. Some trials described patterns such as changes in pain scores observed during the first few days of application.


Follow-up and Long-Term Data

The evidence base for Alvogyl is primarily drawn from research exploring short-term symptom changes. This means that the observation of patient outcomes was limited to short follow-up durations, usually within the first 7 to 10 days after the dressing application. Long-term effects are not fully established because the research was focused on acute symptomatic management. There is limited information for long-term outcomes regarding the final healing and structural repair of the socket tissue beyond the acute phase. The current research provides context but does not determine whether the application of the dressing impacts the longer-term structural outcome.


Limitations and Areas of Research Uncertainty

Several limitations have been noted in the scientific literature summarizing the evidence for Alvogyl. The sample sizes were modest in many of the individual comparative trials, and the evidence quality varies across studies due to differences in how trials were conducted. Data for certain groups remain insufficient, particularly for children, older adults, or individuals with complex health conditions. Due to these factors, the certainty remains low in areas outside of acute symptom management, and more consistent, larger-scale research would contribute to a more comprehensive understanding of the agent's research base.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Alvogyl (FAQ)

Q: Is Alvogyl the same as other products used for the same purpose?

Regulatory descriptions indicate Alvogyl is a specialized combination paste used as a dental dressing. A key feature is its unique composition, including specific fibers that are designed to promote good adherence inside the socket. This formulation allows the dressing to gradually eliminate on its own over time, which differentiates it from standard non-medicated gauze or packing.


Q: Does Alvogyl work right away, or does it take time?

Official product information indicates that the preparation is designed to rapidly alleviate pain. This rapid alleviation is consistent with the quick action of the local anesthetic component, which provides targeted desensitization.


Q: How long does the effect of Alvogyl last?

Alvogyl is designed as a one-step, self-eliminating treatment. The paste is formulated to remain in place and gradually dissipate on its own due to natural processes. The dressing is intended to provide a prolonged soothing effect during the initial healing period as it remains in place.


Q: Is Alvogyl an antibiotic?

Official product information classifies Alvogyl as an antiseptic dental dressing. The Iodoform component provides an antiseptic effect that assists in managing the local bacterial load. However, it is not categorized as a systemic antibiotic drug.


Q: How is Alvogyl different from a standard painkiller?

Alvogyl is applied directly to the extraction site, meaning its analgesic (pain-relieving) action is topical and localized. Unlike standard oral painkillers, which affect the entire body systemically, Alvogyl is intended to provide targeted relief only at the site of administration.


Q: What are the most common things people misunderstand about how to use Alvogyl?

A common point of clarification is related to the removal process. Regulatory documents indicate that the treatment is self-eliminating and does not require manual removal by the dental professional. The paste gradually dissipates from the socket on its own.


Q: Is Alvogyl suitable for children?

Official regulatory documents note that the use of this product is not established in younger populations. Furthermore, official product instructions typically state that the paste should not be used after the extraction of deciduous (baby) teeth.


Q: Is Alvogyl safe for older adults?

Regulatory product information does not list specific restrictions for older adults. However, summaries of clinical research acknowledge that data is insufficient specifically for this patient population.


Q: What does 'contraindicated' mean for Alvogyl?

The term 'contraindicated' means there are absolute reasons that prohibit the use of the medicine. For Alvogyl, this includes patients with known hypersensitivity or allergies to its active components, such as iodine compounds or procaine-type anesthetics.


Q: What is the general expectation for recovery when Alvogyl is used?

The product is used to help rapidly alleviate pain and provide local protection during the initial healing phase. Scientific research on the product typically monitors patient-reported discomfort and pain scores over a short observation period, such as the first seven to ten days after application.


Q: Why do some people confuse Alvogyl with dental gauze or packing?

Alvogyl is officially classified as a dressing, a term also used for gauze or packing. However, Alvogyl is a specialized paste formulation that contains fibers to give it a unique texture and allow it to adhere to the socket, which differentiates it from standard non-medicated gauze.


Q: How quickly do users typically feel less discomfort after Alvogyl is applied?

The product is designed to provide rapid relief from pain due to the action of the local anesthetic component. The intended design suggests that a reduction in discomfort is typically experienced soon after the dressing is placed by the dental professional.


Q: What is the official definition of the condition Alvogyl is used to manage?

The primary condition Alvogyl is used to manage is Alveolar Osteitis, commonly referred to as Dry Socket. This condition is defined as a painful inflammation of the exposed bone in the tooth socket, which occurs following the loss or dissolution of the protective blood clot.


Q: Are there any specific safety warnings listed by regulatory bodies for Alvogyl?

Official warnings state that the product is generally not recommended for routine use in simple or non-complicated extractions. It is also contraindicated for use after the extraction of deciduous (baby) teeth. Its application is reserved strictly for professional dental use.


Q: Does the efficacy of Alvogyl depend on the user's age or gender?

Official regulatory summaries note that the clinical data is insufficient to establish definitive conclusions regarding the use of the dressing in specific age groups, such as children and older adults. Regulatory information does not indicate any dependence of the product's function on the user's gender.


Q: What are the known reasons for treatment failure when using Alvogyl?

Complications in the healing process are typically associated with the localized tissue response to the non-resorbable materials in the dressing. This tissue reaction, sometimes called a Foreign-Body Reaction, can lead to documented issues such as delayed healing or localized infection at the site.


Q: Is it normal to see a color change around the area where Alvogyl is placed?

Yes, a temporary color change at the application site may be observed. This is due to the Iodoform component, which functions by slowly releasing nascent iodine. Iodine compounds are naturally yellow or brown in color.


Q: Is the main benefit of Alvogyl related to protecting the application site?

According to the official product information, a benefit of the dressing is its barrier effect, which protects the application site from superinfection. It is also noted that the presence of the paste in the socket assists in localized hemostasis (managing bleeding).


Q: Can I drive or operate machinery while Alvogyl is being used (general safety classification)?

Official regulatory labels state that the product is unlikely to affect the ability to drive or operate machinery. This is primarily due to its localized route of administration, which restricts the active ingredients to the application site.


Q: Can Alvogyl cause a temporary change in taste?

A temporary change in taste, or dysgeusia, is a sensory effect that has been observed with oral dental products containing components like Iodoform and Eugenol. These active ingredients are known for having distinct aromas and tastes.


Q: Why is detailed information about Alvogyl available on government websites?

Detailed information about Alvogyl is made available by regulatory bodies because it is a licensed medicinal product. Agencies like the MHRA or EMA are legally required to publish the authorized product information (such as the Summary of Product Characteristics) to ensure public access and safety.


Q: Does Alvogyl have a strong scent or taste?

The paste contains components, specifically Iodoform and Eugenol, which are known to have a distinct aroma and taste. For this reason, official safety information often notes a strong scent or taste as a sensory characteristic of the product.


Q: Can I use other oral hygiene products like mouthwash while Alvogyl is in use?

General post-application care instructions often advise patients to avoid mechanical disturbance or chemical irritation to the socket area. Specific post-application instructions advise against vigorous rinsing or the use of strong, alcohol-containing mouthwash, as these actions may disrupt the dressing.


Q: What does the manufacturer advise regarding accidental swallowing?

The product is applied by a dental professional in a small, defined amount for local use only and is not intended to be swallowed. Due to the product being strictly administered in a clinical setting by a professional, regulatory documentation focuses on proper application.


Q: Does Alvogyl affect the clotting process?

Official product information indicates that the paste, when applied, is intended to help manage localized bleeding and clot formation at the application site. It is described as promoting localized hemostasis (the process of stopping bleeding) within the socket.


Q: Is Alvogyl considered a prescription-only medicine?

Regulatory labeling classifies Alvogyl as a preparation Reserved for Professional Dental Use. This means its use is restricted to licensed dental professionals and it is not available to the general public as an over-the-counter or traditional prescription medicine.


Q: Official disposal requirements mandate that unused or expired Alvogyl must be returned to a pharmacist. Does this apply to all regions?

Regulatory disposal instructions specify that the product should be returned to a pharmacist or collected under specific schemes. These procedures must be carried out in accordance with local, regional, and national regulations. This means the exact required disposal method depends on the authority in the patient's specific location.

Advertisements

How should Alvogyl be stored and disposed of?

Official Storage and Disposal Requirements

The storage and disposal of Alvogyl are strictly defined by regulatory labeling to ensure product stability and environmental protection.

Storage Component Official Requirement
Temperature & Environment Store at normal temperature in a cool, dry place. Keep away from food and beverages.
Packaging Integrity The container must be kept carefully and securely closed, and the cap must be replaced immediately after use.
Stability The shelf life is 3 years. Contents must be used within two years of opening.
Child Safety Keep the medicine in a safe place, out of the reach of children.

Disposal Instructions

Official disposal requirements mandate that unused or expired Alvogyl must be returned to a pharmacist. It must not be disposed of with household garbage. To protect the environment, the product should not be allowed to reach sewage systems, water courses, or drains, in accordance with local, regional, and national regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Alvogyl found in:

A-Z Index: